Zymeworks INC

Zymeworks Inc. has entered into a definitive agreement to acquire Theravance Biopharma, Inc. for approximately $929 million, adding the COPD treatment YUPELRI to its portfolio and financing the deal through a combination of cash and a $350 million non-recourse note.

Zymeworks Inc. announced a new $125 million share repurchase program, replacing its previous authorization, and expects its cash resources to fund operations beyond 2028.

Zymeworks Inc. announced the appointment of Kristin Stafford, a seasoned finance executive with extensive life sciences experience, as its new Executive Vice President and Chief Financial Officer, effective April 1, 2026.

Zymeworks has secured $250 million in non-recourse royalty-backed financing from Royalty Pharma, leveraging future Ziihera royalties to bolster its balance sheet and fund strategic initiatives.

Zymeworks reported a 39% revenue increase and reduced net loss in 2025, bolstered by a $250M royalty-backed note and anticipated Ziihera regulatory approvals.

Zymeworks announced a strategic pivot towards asset aggregation, significant leadership changes, and positive clinical data for Ziihera, alongside preliminary cash runway guidance beyond 2028.

Zymeworks Inc. reported a significant increase in Q3 2025 revenue driven by collaboration milestones and royalties, while advancing its wholly-owned oncology and AIID pipeline programs.

Zymeworks Inc. reported a significant increase in Q2 2025 revenue and a substantial reduction in net loss, driven by key milestone payments and initial royalties from its partnered zanidatamab program.

Zymeworks' Q1 2025 results show increased revenue driven by milestone payments and progress in clinical trials, alongside ongoing development of its wholly-owned pipeline.

Zymeworks reports a net loss of $99.2 million for the nine months ended September 30, 2024, while advancing its pipeline of novel biotherapeutics.

Zymeworks' Q2 2024 report details financial results, progress on zanidatamab, and advancements in early-stage pipeline programs.

Zymeworks reports a net loss of $31.7 million for the first quarter of 2024, with a decrease in revenue primarily due to the transfer of the zanidatamab program to Jazz Pharmaceuticals.

Zymeworks Inc. reports a net loss of $81.1 million for 2025, alongside significant regulatory approvals for zanidatamab and a new $250 million royalty financing deal.

Zymeworks' 2024 10-K filing highlights the company's progress in developing biotherapeutics for cancer and autoimmune diseases, including the FDA approval of Ziihera and advancements in its wholly-owned pipeline.

Zymeworks Inc.'s 10-K filing details its capital stock structure, ongoing clinical trials, and strategic partnerships, highlighting its focus on developing novel biotherapeutics.

Zymeworks Inc. reports that Hollywood Mark, EVP & Chief Operating Officer, acquired 939 shares of common stock through the company's Employee Stock Purchase Plan on July 6, 2026.

Zymeworks Inc. EVP and General Counsel Paul R. Schneider was granted 178,000 stock options and 119,000 restricted stock units.

Adam Schayowitz, EVP of Research & Development at Zymeworks Inc., reported transactions involving stock options and restricted stock units.

Zymeworks Inc. EVP Scott Platshon filed a Form 4 detailing transactions involving stock options, restricted stock units, and performance stock units.

Kristin Stafford, EVP and CFO of Zymeworks Inc., was granted stock options and restricted stock units on April 6, 2026.

Zymeworks Inc.'s EVP & Chief Operating Officer, Mark Hollywood, reported the vesting of restricted stock units and the acquisition of new stock options and performance stock units, alongside a tax-related stock sale.

Zymeworks Inc. announced its Annual Meeting of Stockholders for December 30, 2025, to address director elections, executive compensation, and auditor ratification.

Zymeworks Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on December 30, 2025, focusing on director elections, executive compensation, and auditor ratification, alongside reporting 2024 financial and operational highlights.

Zymeworks Inc. will hold its annual stockholder meeting on December 10, 2024, to vote on the election of directors, executive compensation, and the ratification of auditors.

Zymeworks Inc. will hold its annual meeting of stockholders on December 10, 2024, to elect directors, approve executive compensation, and ratify the appointment of auditors.

Activist investor EcoR1 Capital, LLC, and its affiliates, now beneficially own 30.7% of Zymeworks Inc. common stock, with an EcoR1 employee appointed Acting Chief Investment Officer.

EcoR1 Capital, LLC and its affiliates have substantially increased their beneficial ownership in Zymeworks Inc. to 30.7% of outstanding common stock following the full exercise of pre-funded warrants.

EcoR1 Capital, along with Oleg Nodelman, has increased its beneficial ownership in Zymeworks Inc. to 25.4%, asserting significant influence through board representation and a substantial investment in common stock and pre-funded warrants.

Investment firm EcoR1 Capital, along with its affiliates, has increased its beneficial ownership in Zymeworks Inc. to 24.2% and secured two board seats, signaling an active investment approach.

Investment firm EcoR1 Capital, along with its affiliates, has increased its beneficial ownership in Zymeworks Inc. to 22.8% and secured a board seat for its manager, Oleg Nodelman, signaling a deeper strategic involvement.

EcoR1 Capital, LLC and its affiliates have increased their beneficial ownership in Zymeworks Inc. to 22.4% of outstanding common stock, reiterating their belief in the company's undervaluation and potential for strategic influence.

Perceptive Advisors LLC and Joseph Edelman have reported a 5.4% beneficial ownership stake in Zymeworks Inc. via a Schedule 13G filing.

Rubric Capital Management LP and David Rosen have disclosed a 7.68% beneficial ownership stake in Zymeworks Inc., totaling 5,750,000 common shares.

Morgan Stanley has filed an amended Schedule 13G, reporting its beneficial ownership in Zymeworks Inc. has fallen to 3.4%.

Biotechnology Value Fund and its affiliates have increased their aggregate beneficial ownership in Zymeworks Inc. to 5.2% of outstanding common stock as of September 30, 2025.

Redmile Group, LLC and its principal, Jeremy C. Green, have disclosed a 4.9% beneficial ownership stake in Zymeworks Inc., totaling 3,705,750 shares.

Redmile Group, LLC and its principal Jeremy C. Green have disclosed a 5.6% beneficial ownership stake in Zymeworks Inc. common stock.